Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Gains from Investment Securities (2016 - 2025)

Perspective Therapeutics' Gains from Investment Securities history spans 13 years, with the latest figure at -$14000.0 for Q3 2025.

  • For Q3 2025, Gains from Investment Securities changed N/A year-over-year to -$14000.0; the TTM value through Sep 2025 reached -$59000.0, down 100.01%, while the annual FY2024 figure was $3.0 million, 41.43% down from the prior year.
  • Gains from Investment Securities for Q3 2025 was -$14000.0 at Perspective Therapeutics, up from -$84000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $609.6 million in Q4 2023 and bottomed at -$138000.0 in Q1 2025.
  • The 5-year median for Gains from Investment Securities is $138500.0 (2022), against an average of $40.1 million.
  • The largest annual shift saw Gains from Investment Securities surged 60958400.0% in 2023 before it tumbled 806.67% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $7.3 million in 2021, then tumbled by 99.99% to $1000.0 in 2022, then soared by 60958400.0% to $609.6 million in 2023, then plummeted by 99.97% to $177000.0 in 2024, then tumbled by 107.91% to -$14000.0 in 2025.
  • Per Business Quant, the three most recent readings for CATX's Gains from Investment Securities are -$14000.0 (Q3 2025), -$84000.0 (Q2 2025), and -$138000.0 (Q1 2025).